scholarly journals The results of the open observational, international, multicenter, prospective program to assess the efficacy, safety and tolerability of the first direct renin inhibitor RasilezR (aliskiren) in patients with arterial hypertension in ‘real-life’ clinical practice settings (DRIve)

2014 ◽  
Vol 11 (3) ◽  
pp. 5-6
Author(s):  
I Ye Chazova
Keyword(s):  
Arterial Hypertension ◽  
Real Life ◽  
Renin Inhibitor ◽  
Patient Acceptance ◽  
Renin Inhibitors ◽  
Direct Renin Inhibitor ◽  
Direct Renin Inhibitors ◽  
Real Life Setting ◽  
Multicenter Prospective Study ◽  
International Multicenter

Rasilez® (aliskiren) is the first drug from direct renin inhibitors class (DRI), which is used to treat arterial hypertension. The first aim of the «DRIve» program (Open observational, international, multicenter, prospective study to assess the efficacy, safety and tolerability of the first direct renin inhibitor Rasilez® (aliskiren) in patients with arterial hypertension in a real life setting) is to collect information about the efficacy, safety and tolerability of Rasilez (aliskiren) in monotherapy or in combination with other drugs in a real life setting for 6 months of therapy. Secondary aims were to analyze the patient acceptance of therapy and additional factors determining the outcome of Rasilez treatment. The program had been holding out from October 2009 until July 2011 in 17 cities of Russia.

Hypertension Management and End Organ Protection: Focus on Aliskiren

2009 ◽  
Vol 1 ◽  
pp. CMT.S1980
Author(s):  
Toshio Imanishi ◽  
Hiroto Tsujioka ◽  
Takashi Akasaka
Keyword(s):  
Ace Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Renin Angiotensin System ◽  
Plasma Renin ◽  
Renin Inhibitor ◽  
Organ Protection ◽  
Renin Inhibitors ◽  
Direct Renin Inhibitor ◽  
Key Factor ◽  
Receptor Blockers

The renin-angiotensin system (RAS) activity is a key factor in the pathophysiology and development of hypertension, atherosclerosis, heart failure, and renal disease. It is unclear whether angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) have fully delivered the expected reductions in cardiovascular risk. In fact, the optimized RAS suppression is difficult to achieve with these agents, partly because ACE inhibitors and ARBs both activate compensatory feedback mechanisms that result in renin release and increase plasma renin activity (PRA). Molecular modeling was used to develop aliskiren, a potent, low-molecular-weight, nonpeptide, direct renin inhibitor with sufficient bioavailability to produce sustained suppression of PRA after oral administration. This report discusses the mechanisms of action of oral renin inhibitors and their pharmacokinetic properties. In addition, the report also evaluates the available data regarding the effects of the renin inhibitor aliskiren in the treatment of hypertension and related cardiovascular disorders.

MANAGEMENT OF RESECTION OF LARGE COLONIC LESIONS IN A REAL-LIFE SETTING: THE SCALP STUDY

2018 ◽  
Author(s):  
A Amato ◽  
F Radaelli ◽  
V Cennamo ◽  
E Di Giulio ◽  
L Fuccio ◽  
...  
Keyword(s):  
Real Life ◽  
Real Life Setting

130-LB: Retrospective Evaluation of Treatment Patterns in a Real-Life Setting Environment with Dapagliflozin or DPP-4 Inhibitors as Add-On Therapy in Uncontrolled DM2 Patients Who Previously Failed on Other Regimens

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 130-LB
Author(s):  
DIEGO ESPINOZA-PERALTA ◽  
ARNULFO GONZÁLEZ-CANTÚ ◽  
ALEJANDRA I. SILVA ◽  
JUAN G. COLLADO ◽  
JORGE DAVID ROGEL-MANZANARES ◽  
...  
Keyword(s):  
Real Life ◽  
Treatment Patterns ◽  
Retrospective Evaluation ◽  
Real Life Setting

Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension

2011 ◽  
pp. 1 ◽  
Author(s):  
Domenic Sica ◽  
Alan H. Gradman ◽  
Ole Lederballe ◽  
Rainer E. Kolloch ◽  
Jack Zhang ◽  
...  
Keyword(s):  
Renin Inhibitor ◽  
Direct Renin Inhibitor
Sign in / Sign up

Export Citation Format

Share Document